MX2024006393A - Tratamiento de enfermedad desmielinante del sistema nervioso central (snc) con satralizumab. - Google Patents
Tratamiento de enfermedad desmielinante del sistema nervioso central (snc) con satralizumab.Info
- Publication number
- MX2024006393A MX2024006393A MX2024006393A MX2024006393A MX2024006393A MX 2024006393 A MX2024006393 A MX 2024006393A MX 2024006393 A MX2024006393 A MX 2024006393A MX 2024006393 A MX2024006393 A MX 2024006393A MX 2024006393 A MX2024006393 A MX 2024006393A
- Authority
- MX
- Mexico
- Prior art keywords
- demyelinating disease
- cns
- treatment
- nervous system
- central nervous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2021/043459 WO2023095305A1 (en) | 2021-11-26 | 2021-11-26 | Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab |
| PCT/JP2022/039605 WO2023095510A1 (en) | 2021-11-26 | 2022-10-25 | Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006393A true MX2024006393A (es) | 2024-06-04 |
Family
ID=86539186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006393A MX2024006393A (es) | 2021-11-26 | 2022-10-25 | Tratamiento de enfermedad desmielinante del sistema nervioso central (snc) con satralizumab. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250034265A1 (https=) |
| JP (1) | JP2024543147A (https=) |
| KR (1) | KR20240107372A (https=) |
| CN (1) | CN118591389A (https=) |
| AU (1) | AU2022398430A1 (https=) |
| CA (1) | CA3238940A1 (https=) |
| IL (1) | IL313058A (https=) |
| MX (1) | MX2024006393A (https=) |
| TW (1) | TW202330030A (https=) |
| WO (3) | WO2023095305A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| IL287220B2 (en) | 2019-04-17 | 2026-03-01 | Univ Hiroshima | A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor |
| AU2021278562A1 (en) | 2020-05-29 | 2022-12-01 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing formulation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2206775B1 (en) | 2007-09-26 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-il-6 receptor antibody |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US20120039840A1 (en) | 2008-12-02 | 2012-02-16 | Hunter Christopher A | Use of IL-27-P28 to antagonize IL-6 mediated signaling |
| JP6130983B2 (ja) * | 2015-02-27 | 2017-05-17 | 中外製薬株式会社 | Ｉｌ−６関連疾患治療用組成物 |
-
2021
- 2021-11-26 WO PCT/JP2021/043459 patent/WO2023095305A1/en not_active Ceased
-
2022
- 2022-10-25 CA CA3238940A patent/CA3238940A1/en active Pending
- 2022-10-25 AU AU2022398430A patent/AU2022398430A1/en active Pending
- 2022-10-25 JP JP2024531227A patent/JP2024543147A/ja active Pending
- 2022-10-25 KR KR1020247021082A patent/KR20240107372A/ko active Pending
- 2022-10-25 MX MX2024006393A patent/MX2024006393A/es unknown
- 2022-10-25 WO PCT/JP2022/039605 patent/WO2023095510A1/en not_active Ceased
- 2022-10-25 TW TW111140385A patent/TW202330030A/zh unknown
- 2022-11-25 IL IL313058A patent/IL313058A/en unknown
- 2022-11-25 WO PCT/JP2022/043437 patent/WO2023095852A1/en not_active Ceased
- 2022-11-25 CN CN202280089989.0A patent/CN118591389A/zh active Pending
- 2022-11-25 US US18/712,917 patent/US20250034265A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118591389A (zh) | 2024-09-03 |
| US20250034265A1 (en) | 2025-01-30 |
| TW202330030A (zh) | 2023-08-01 |
| WO2023095305A1 (en) | 2023-06-01 |
| JP2024543147A (ja) | 2024-11-19 |
| WO2023095510A1 (en) | 2023-06-01 |
| KR20240107372A (ko) | 2024-07-09 |
| IL313058A (en) | 2024-07-01 |
| CA3238940A1 (en) | 2023-06-01 |
| WO2023095852A1 (en) | 2023-06-01 |
| AU2022398430A1 (en) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006393A (es) | Tratamiento de enfermedad desmielinante del sistema nervioso central (snc) con satralizumab. | |
| MX2024007724A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado | |
| MX2023001726A (es) | Anticuerpos anti-c5 y usos de los mismos. | |
| PH12019501773A1 (en) | Anti-ccr7 antibody drug conjugates | |
| CR20220660A (es) | Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2 | |
| DK1951759T3 (da) | Anti-EGFR-antistoffer | |
| MX2010003380A (es) | Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina. | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| WO2020014097A8 (en) | Reagents and methods for treating cancer and autoimmune disease | |
| NZ595005A (en) | Treatment of insulin-resistant disorders | |
| PH12022500030A1 (en) | Anti-tgfã antibodies and therapeutic uses thereof | |
| ZA202213434B (en) | Anti-lilrb1 antibody and uses thereof | |
| MX2023004020A (es) | Anticuerpos anti-ngf y métodos para su uso. | |
| MY210018A (en) | Monoclonal antibody that binds specifically to gitr | |
| PH12022552741A1 (en) | Anti-ox40 antibody and uses thereof | |
| MX2024008835A (es) | Tratamiento con encefalitis autoinmune con satralizumab. | |
| MX2022008471A (es) | Anticuerpo anti-angptl3 y uso del mismo. | |
| MX2025004652A (es) | Conjugados de farmaco-anticuerpo del cumulo de diferenciacion (cd70) y metodos de uso de los mismos | |
| MX2025003153A (es) | Anticuerpos anti-ccr8 | |
| MX2024014232A (es) | Anticuerpo anti-b7h3 y usos del mismo | |
| CR20230528A (es) | Anticuerpo anti componente del complemento 1s (c1s) | |
| MX2025012052A (es) | Molecula de union a antigeno que se une especificamente a egfr y muc1, conjugado farmaceutico del mismo y uso medico del mismo | |
| CA3242378A1 (en) | Anti-musk antibodies for use in treating neuromuscular disorders | |
| MX2026000793A (es) | Anticuerpo muc1 humanizado y conjugado anticuerpo-farmaco | |
| MX2022005718A (es) | Anticuerpos tmem219 y usos terapeuticos de los mismos. |